Field Trip Health announces $50 million bought deal

Field Trip Health announces $50 million bought deal
Share this article

 

TORONTO – Field Trip Health Ltd. (CSE: FTRP; FTRP.WT; OTCQX: FTRPF), a leader in the development and delivery of psychedelic therapies, announced it has entered into an agreement with Bloom Burton Securities Inc. on a “bought deal” basis for 7,692,310 common shares of the company at a price of $6.50 per common share, for aggregate gross proceeds of $50,000,015. In the event that the over-allotment option is exercised in its entirety, the aggregate gross proceeds of the offering will be $57,500,014. Field Trip intends to use the net proceeds from the offering for the ongoing development of the “FT-104” novel psychedelic development program, the opening of new Field Trip Health centers, and for working capital and general corporate purposes. All dollar amounts referenced are expressed in Canadian Dollars.

Field Trip is a global leader in the development and delivery of psychedelic therapies. The Field Trip Discovery division is leading the development of the next generation of psychedelic molecules and conducting advanced research on plant-based psychedelics including psilocybin-producing fungi. The Field Trip Health division is building centers for psychedelic therapies opening across North America and Europe along with the digital and technological tools that will enable massive scale. Field Trip aims to help people from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

We seek Safe Harbor.

Related posts

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.